Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia
NCT03996486 · Bayer · PHASE1 · withdrawn · last registry update 2019-10-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Company decision” | – | Registry record, Bayer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TFPI within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-08-19Results posted on the registry: Portola Pharmaceuticals, Andexanet alfa (bolus) + Betrixaban 80 mg PO QD (NCT03330457)
- 2020-08-14Results posted on the registry: Portola Pharmaceuticals, Andexanet alfa + Apixaban (NCT03310021)
- 2019-12-04Results posted on the registry: Pfizer, PF-06741086 + PF-06741086 (NCT02974855)
- 2019-09-10Phase 3 first posted: Novo Nordisk A/S, Concizumab (NCT04083781)
- 2019-09-09Phase 3 first posted: Novo Nordisk A/S, Concizumab (NCT04082429)
- 2019-05-06Phase 3 first posted: Pfizer, PF-06741086 (NCT03938792)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision